First Manhattan’s DexCom DXCM Stock Holding History

First Manhattan’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,396	Closed	-$194K	–	832
2024 Q1	$194K	Sell	1,396 -380	-21%	-$47.8K	﹤0.01%	661
2023 Q4	$220K	Buy	1,776 +126	+8%	+$12.9K	﹤0.01%	633
2023 Q3	$154K	Buy	1,650 +3	+0.2%	+$338	﹤0.01%	695
2023 Q2	$212K	Buy	1,647 +107	+7%	+$12.9K	﹤0.01%	653
2023 Q1	$179K	Buy	1,540 +380	+33%	+$42.5K	﹤0.01%	698
2022 Q4	$131K	Buy	1,160 +760	+190%	+$83.4K	﹤0.01%	782
2022 Q3	$32K	Hold	400	–	–	﹤0.01%	1003
2022 Q2	$29K	Hold	400	–	–	﹤0.01%	1060
2022 Q1	$51K	Hold	400	–	–	﹤0.01%	1000
2021 Q4	$53K	Hold	400	–	–	﹤0.01%	983
2021 Q3	$54K	Hold	400	–	–	﹤0.01%	978
2021 Q2	$42K	Hold	400	–	–	﹤0.01%	1017
2021 Q1	$35K	Buy	400 +200	+100%	+$18.8K	﹤0.01%	1030
2020 Q4	$18K	Hold	200	–	–	﹤0.01%	1067
2020 Q3	$20K	Sell	200 -172	-46%	-$18K	﹤0.01%	1022
2020 Q2	$37K	Buy	372 +200	+116%	+$17.9K	﹤0.01%	928
2020 Q1	$11K	Buy	+172	New	+$10.7K	﹤0.01%	1120
2018 Q1	–	Sell	-15,596	Closed	-$223K	–	1397
2017 Q4	$223K	Buy	+15,596	New	+$203K	﹤0.01%	695

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Manhattan's DXCM Position: Q2 2024 in Review

First Manhattan sold out of DexCom (DXCM) in Q2 2024, closing a stake of 1,396 shares — an estimated $194K sold.

First Manhattan first reported a position in DXCM in Q4 2017 and held it in 18 quarters. The position peaked at $223K in Q4 2017. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

First Manhattan reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 1,396 DexCom shares in Q2 2024, an estimated $194K.
First Manhattan first reported a position in DexCom in Q4 2017 and held it in 18 quarters.
First Manhattan's DexCom position peaked at $223K in Q4 2017.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.